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Abstract
African trypanosomes of the Trypanosoma brucei species are extra-cellular parasites that cause human African
trypanosomiasis (HAT) as well as infections in game animals and livestock. Trypanosomes are known to evade the
immune response of their mammalian host by continuous antigenic variation of their surface coat. Here, we aim to
demonstrate that in addition, trypanosomes (i) cause the loss of various B cell populations, (ii) disable the hosts’ capacity to
raise a long-lasting specific protective anti-parasite antibody response, and (iii) abrogate vaccine-induced protective
response to a non-related human pathogen such as Bordetella pertussis. Using a mouse model for T. brucei, various B cell
populations were analyzed by FACS at different time points of infection. The results show that during early onset of a T.
brucei infection, spleen remodeling results in the rapid loss of the IgM
+ marginal zone (IgM
+MZ) B cell population
characterized as B220
+IgM
HighIgD
Int CD21
HighCD23
LowCD1d
+CD138
2. These cells, when isolated during the first peak of
infection, stained positive for Annexin V and had increased caspase-3 enzyme activity. Elevated caspase-3 mRNA levels
coincided with decreased mRNA levels of the anti-apoptotic Bcl-2 protein and BAFF receptor (BAFF-R), indicating the onset
of apoptosis. Moreover, affected B cells became unresponsive to stimulation by BCR cross-linking with anti-IgM Fab
fragments. In vivo, infection-induced loss of IgM
+ B cells coincided with the disappearance of protective variant-specific T-
independent IgM responses, rendering the host rapidly susceptible to re-challenge with previously encountered parasites.
Finally, using the well-established human diphtheria, tetanus, and B. pertussis (DTPa) vaccination model in mice, we show
that T. brucei infections abrogate vaccine-induced protective responses to a non-related pathogen such as B. pertussis.
Infections with T. brucei parasites result in the rapid loss of T–cell independent IgM
+MZ B cells that are normally functioning
as the primary immune barrier against blood-borne pathogens. In addition, ongoing trypanosome infections results in the
rapid loss of B cell responsiveness and prevent the induction of protective memory responses. Finally, trypanosome
infections disable the host’s capacity to recall vaccine-induced memory responses against non-related pathogens. In
particular, these last results call for detailed studies of the effect of HAT on memory recall responses in humans, prior to the
planning of any mass vaccination campaign in HAT endemic areas.
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Introduction
African trypanosomes that belong to the T. brucei species are
extracellular parasites that cause Human Afican Trypanosomiasis
(HAT) and Nagana, a wasting disease of cattle. As a defense
barrier against the host immune response, the entire surface of the
T. brucei parasite is covered with 10
7 densely packed molecules of a
variant surface glycoprotein (VSG) that determines the antigenic
phenotype of the parasite [1,2,3]. At any given time, a single VSG
gene encodes for all the VSG molecules present on the
trypanosome surface, creating a homogenous antigenic coat.
There are at least 1000 different VSG genes present within the T.
brucei genome [3,4,5]. In addition, these VSG genes undergo
extensive recombination generating an extremely large and plastic
antigenic repertoire. The ability to switch expression from one
VSG to another is considered to be the major mechanism allowing
the parasite to evade an efficient host antibody response, hence
preventing parasite elimination and permitting the establishment
of a chronic infection [3,6]. In addition, the extreme degree of
antigenic variation exhibited by African trypanosomes is consid-
ered to be the main reason for the failure of anti-trypanosome
vaccination strategies to date [7].
Experimental T. brucei infections in mice are widely used to
study host pathogen interactions [8,9], and serve as models for
anti-trypanosome vaccine development [10]. These infections are
characterized by the recurring appearance of peaks of parasitemia
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(VATs) of the parasite. Parasite elimination from the blood, lymph
and various host tissues can result from combined antibody-
mediated killing, nitric oxide and cytokine toxicity, and parasite
growth arrest in response to host and parasite-derived quorum-
sensing factors [9,11,12,13,14,15]. During the first days of
infection, mice generate a rapid IgM response, followed by an
immunoglobulin isotype switch and secretion of high levels of
IgG2a, IgG2b and IgG3 antibodies [16]. Although infections
trigger both a T-dependent and a T-independent antibody
response, host resistance was shown to be mainly dependent on
the latter and functions through a complement independent
mechanism. Indeed, trypanosome infected athymic mice as well as
complement-deficient mice mount an effective antibody response
and control parasite growth with similar kinetics as observed in
wild-type mice [16,17,18]. Interesting to note is that while early
induction of anti-trypanosome antibody responses aids in the
effective VAT-specific clearance of the first peak of parasitemia,
mice lose the capacity to control T. brucei growth later during
infection, and usually die due to multi-organ failure with high
circulating parasite loads in the presence of high levels of anti-VSG
antibodies [16,18]. Interestingly, while polyclonal B cell activation
was found to be a hallmark of the infection with human infective
parasites [19,20] and in trypanosome infected domestic animals
[21], the mechanisms underlying this process are still not fully
understood. It has been proposed that early on during infection,
the densely packed VSG coat can be recognized as a highly
repetitive and structured single-epitope array implicated in
abnormal B cell activation as well as exhaustion [22].
To date, little is known about the fate of specific B cell
populations and the tissue re-modeling during trypanosome
infections, although early studies have reported changes in splenic
B cell content indicating high cellular infiltration into the spleen.
In general, the earliest B cells that migrate from bone marrow
(BM) to the spleen are transitional type 1 (T1) B cells. These cells
develop locally into transitional type 2 (T2), and next into
marginal zone (MZ) B cells or mature follicular (Fo) B cells. MZ B
cells play an important role in the early phases of antibody
responses against mainly T-independent antigens [23,24,25]. As
T-independent B cell responses are crucial for early control of T.
brucei, the role and fate of MZ B cells was further analyzed here.
Splenic MZ B cells can be characterized as B220
+IgM
HighIg-
D
IntCD21
HighCD23
LowCD1d
+CD138
2 [26]. Overall, B cell
differentiation and survival is regulated by the B cell-activating
factor (BAFF), a member of the TNF family. BAFF-R, one of the
three BAFF receptors, is expressed on B cells and controls overall
B cell homeostasis [27]. The binding of the BAFF to BAFF-R
promotes NF-kB activation and increases mRNA levels of the
anti-apoptotic factor Bcl-2 [28]. Despite these data, and despite
the fact that T. brucei infections were reported to induce B cell
unresponsiveness to mitogenic stimuli [29,30,31], trypanosome-
induced B cell apoptosis has not received major attention so far. In
general, apoptosis occurs in several pathological and non-
pathological conditions and constitutes a part of a mechanism of
cell replacement and tissue re-modeling, leading to maintenance of
cellular homeostasis [32,33]. The apoptotic process is character-
ized by the series of morphological changes such as cell shrinkage,
chromatin condensation, and DNA fragmentation. Here, the
family of caspases plays a central role, with the activation of
caspase-3 by the release of cytochrome C regarded as a primary
mechanism involved in apoptosis and the degradation of
chromosomal DNA [34]. The anti-apoptotic Bcl-2 protein
counteracts this process by inhibiting the release of cytochrome
C, which in turn blocks activation of caspase-3 [35].
Given the crucial role of T-independent IgM responses in
trypanosomiasis control, and the lack of data on the fate of B cell
populations and in particular IgM
+MZ B-cells during infection,
this paper focuses on this rather neglected part of the host immune
response.
Here we demonstrated that extensive remodeling of spleen
micro-architecture takes place early after T. brucei infection. This
event coincides with the drastic reduction in IgM
+MZ B cells.
Moreover, the loss of IgM
+ B cells after in vivo infection rendered
mice susceptible to a challenge with a previously encountered T.
brucei variant antigenic type. Together, our data indicates that
while antigenic variation might aid in perpetuating a T. brucei
infection within a given host, active infection-driven elimination of
IgM
+ B cells renders a host susceptible to repetitive infections by
the same antigenic type trypanosome. Moreover, in this paper we
demonstrated that T. brucei infection can also abrogate vaccine
induced protective responses that were generated against non-
related pathogens such as Bordettela pertussis (B. pertussis), using a
human vaccine against diphtheria, tetanus and B. pertussis (DTPa)
in a mouse vaccination model.
Materials and Methods
Parasites and infection in mice
The pleomorphic AnTat 1.1E (EATRO 1125 stock) T. brucei
brucei was used in this study as previously described [12]. This
infection is characterized by a multi-wave parasitemia develop-
ment, in which every wave represents a parasite population of
different antigenic type. Mice were infected by i.p. injection of
5000 parasites/mouse. Every 2 to 3 days, the number of parasites
present in the blood was estimated using a counting chamber and
a light microscope. For re-challenge experiments, cloned mono-
morphic T. b. brucei AnTat 1.1E or control monomorphic T. b.
brucei MITat 1.4 parasites were used. These clones are character-
ized by the rapid killing of their host, expressing one single VAT
and their lack of antigentic variation during the 4 day infection.
The homogenic expression of AnTat 1.1 VSG and MITat 1.4
VSG was verified here by RT-PCR followed by VSG sequence
analysis. Re-challenge experiment of AnTat 1.1E infected mice
was performed on day 10 and 17 by administering 5000 cloned
Author Summary
African trypanosomes are extracellular parasites that cause
the deadly disease sleeping sickness in humans, and
nagana in cattle. The control of infection is believed to be
largely dependent on the host antibody response. We
postulate here that protective anti-trypanosome responses
mainly involve splenic marginal zone B cells, as they are
implicated in the production of antibodies against blood-
borne pathogens. In this work, we show that trypanosome
infections induce the rapid loss of these marginal zone B
cells, coinciding with the loss of the splenic marginal zone
itself. While the infection does result in the induction of
plasma cell differentiation and antibody secretion, the loss
of the marginal zone B cell population results in the loss of
specific protective responses. In addition, we also show
that host memory responses are destroyed during
infection, even affecting unrelated vaccine-induced mem-
ory responses such as those induced by the commercially
available DTPa vaccine. The latter finding is crucial for the
evaluation of mass vaccination approaches in African
regions where trypanosome infections are prevalent.
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challenge experiments were performed using the following female
mice: Balb/c and C57BL/6 (Harlan), and mMT B cell deficient
mice as well as nu/nu mice on the C57BL/6 background (both a
kind gift of Prof. B. Ruffel, CNRS). All mice were housed in the
Animal Facility under barrier conditions. The appropriate
university’s ethics committees approved all experimental animal
procedures.
B cell proliferation
B cell proliferation assays were performed using splenic B cells
from infected or non-infected mice. Cells from day 10 post
infection were purified on CD19 MACS separation columns
(Miltenyi Biotec). Aliquots of eluted B cells (5610
4/ml) were
stimulated with different concentration of LPS or anti-IgM Fab
fragments. After 24 hours, cells were pulsed with 1 mCi (
3H)
thymidine (AEC Amersham Uppsala, Sweden) and incubated for a
further 18 hours.
Flow cytometry
B cells were analyzed by flow cytomerty. Spleens were harvested
from infected and non-infected mice at different time points of
infection. Cell suspensions were prepared in complete RPMI
1640. Non-specific binding sites were blocked for 30 min at 4uC,
using ice-cold PBS supplemented with 1% normal rat serum and
2.4G2 the anti-FccR antibody. After washing twice, cells were
stained with the following anti-mouse antibodies: anti-IgM, anti-
IgD, anti-CD21, anti-CD23, anti-B220, anti-CD1d, anti-CD138,
anti-GL7, anti-PNA, coupled to either FITC, or PE. All antibodies
were purchased from BD Biosciences (San Jose, CA). Incubations
were conducted for 30 min at 4uC. For analysis of apoptosis, cells
were simultaneously stained with Annexin V (BD Bioscience) and
7AAD (BD, Biosciences) according to protocols provided by the
manufacturers, in combination with the B-cell markers listed
above. Stained cells were analyzed on a FACS-Calibur SE flow
cytometer (BD Biosciences). Prior to analysis, PI (propidiun iodide)
was added to all cell suspension in order to exclude dead cells from
the data acquisition. All data was analyzed using the FlowJo (Tri
Star) software package.
Quantitative Real-Time PCR
Gene expression levels were measured by Quantitative Real
Time PCR, using the Roche/SYBR green system. B cells from
infected and non-infected mice were purified using CD19
magnetic beads. Total mRNA was extracted using Trizol reagent
according to the instructions supplied by the manufacturer
(Invitrogen). Residual DNA was digested using Turbo DNase kit
from Ambion. Reverse transcription was performed using protocol
supplied by Invitrogen. Real-time PCR reactions were performed
according to the Roche protocol, which included data analysis by
‘Fit Points’, normalization against 18S expression, and ‘Standard
Curve Analysis’.
The following primer pairs were used for PCR amplifications:
Bcl2 Forward: 59- TGGCGCAAGCCGGGAGAACA -39
Bcl2 Reverse: 59- CCCGGTGCACAGCGGGCATT -39
Caspase-3 Forward: 59- CGGATGTGGACGCAGCCAACC
Caspase-3 Reverse: 59- CCCCGGCAGGCCTGAATGATGA
BAFF-R Forward: 59- CTCGTCGGTGCCCCCGCACT
BAFF-R Reverse: 59- GCGTGGCAGGGCGCTGTCTG
18S Forward: 59- GGGCGTGGGGCGGAGATATGC
18S Reverse: 59- CGCGGACACGAAGGCCCCAAA
Western Blot
Spleens were removed from infected (day 7 post-infection) and
non-infected mice. CD21
HighCD23
Low MZ B cells were sorted
using a FACSVantage (BD bioscience) and used for lysate
preparation. Cells were re-suspended in ice-cold PBS supplement-
ed with complete protease inhibitors (Roche). Cell suspensions
were sonicated 3 times on ice by delivering the impulse for 30
seconds. Cellular lysate was spun down at 100.0006g for 30 min
at 4uC and a soluble fraction was collected. Protein concentration
was determined by BCA colorimetric assay (Pierce). 5 mgo f
soluble proteins were submitted to reducing conditions and
separated on SDS PAGE followed by a transfer onto a
nitrocellulose. Nitrocellulose membranes were incubated in
1%BSA/Tris pH 8.0 for 1 hour at room temperature in order
to block non-specific binding sites. Membranes were washed 5
times with Tris pH 8.0/0.05% Tween 20 solution and incubated
with anti-caspase-3 (BD/Pharmingen, clone C92-605, rabbit IgG)
antibody diluted 1000 times in 1%BSA/Tris buffer pH 8.0,
recognizing mouse pro-caspase 3 as well as the activation cleaved
12 KD and 17 kD caspase 3 products. Next, washed membranes
were incubated with a secondary goat anti-rabbit IgG biotinylated
antibody (30,000 diluted in Tris buffer) for 1 hour at room
temperature. After a washing step, streptavidine/alkaline phos-
phatase (Sigma) was added to the membranes and incubated for
one hour at room temperature. Proteins were visualized by using
BCIP/NBT substrate solution from Sigma according to the
manufacturer instructions.
Immunohistochemistry
Spleens were removed from control and infected mice at day 10
post infection. They were embedded in Tissue-Tek (Sakura
Finetek USA, Torrance, California, United States), frozen on
dry ice and stored at 280uC. Cryostat sections (6–8-mm thick)
were fixed in ice-cold acetone for 10 min, rehydrated in PBS, and
treated for 30 min with PBS 1% blocking reagent (PBS-BR)
(Boehringer Mannheim, Mannheim, Germany). Obtained cryo-
sections were washed in PBS and stained for 60 min with the
following biotinylated-labeled antibodies: MOMA-1 (anti-metallo-
phillic marginal macrophages (MMM)) and ERTR-9 (anti-
marginal zone macrophages (MZM) (BMA Biomedicals, Augst,
Switzerland) resuspended in PBS-BR buffer. Next, the sections
were washed in PBS and incubated for 30 min with the secondary
detection reagents streptavidin-FITC and streptavidin-Cy3
(Zymed Laboratories, Invitrogen, Carlsbad, California, United
States) in PBS-BR for MZM and MMM visualization, respective-
ly. The slides were washed in PBS and mounted in anti-fading
GEL/MOUNT (Biomeda, Foster City, California, United States).
Digitized images were captured using a Zeiss AxioCam color
camera and analyzed using the Photoshop software (Adobe
Systems, San Jose, California, United States).
Diphtheria, tetanus and Bordetella pertussis (DTPa)
vaccination scheme and trypanosome challenge
BALB/c neonatal mice were vaccinated according to the
previously published protocol [36,37]. In short, neonatal mice
were vaccinated with one quarter of a human dose of the
commercially available DTPa vaccine (BoostrixH) administered
sub-cutaneous (s.c.). After 21 days, mice received a s.c. booster
injection with the same amount of vaccine. After a further 14 days
mice were infected i.p with 5000 T. brucei parasites/mouse. Ten
days post-infection, mice received an intranasal dose of 5610
6 B.
pertussis bacteria/mouse (ATCC9797) in 10 ml PBS. Control mice
received the intranasal B. pertussis challenge in the absence of a
B-Cell Dysfunction in Trypanosomiasis
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parasite infection. Lung bacterial load clearance was monitored
after 3 hours, and 3, 5, 8 days post-challenge. Mice were sacrificed
and whole lungs were isolated and homogenized in 5 ml PBS.
Serial 10 fold dilutions were prepared and aliquots of 200 ml were
plated onto the Bordet-Gongaou agar plates. The number of
colony forming units (CFU’s) was counted after 72 hours of
incubation at 36uC.
Results
T. brucei infections induce both an early loss of Marginal
Zone (IgM
+MZ) B cells and an increase in splenic plasma
cells
Induction of a T-independent anti-trypanosome IgM response
has been shown to be a crucial factor in T. brucei parasite
elimination. As IgM
+MZ B cells are the main mediators of T-
independent antigen responses, the fate of this population was
addressed in an experimental C57Bl/6 mouse T. brucei AnTat 1.1
infection model. Here, the trypanosome infection is characterized
by multiple waves of parasitemia and a survival of about 35-40
days [16]. Hence, spleens were isolated at different time points
during infection and prepared for cellular characterization by
FACS. Multiple surface staining combinations can be used to
characterize MZ B cells, with CD21/CD23, IgM/IgD and B220/
CD1d as the most common combinations [26]. Figure 1A (upper
panel) shows that all three combinations give similar MZ B cell
counts when spleen populations of naı ¨ve non-infected mice were
analyzed, with CD21
HighCD23
Low (R1)=2.25%, IgM
HighIgD
Int
(R2)=2.39% and B220
+CD1d
+ (R3)=2.37%. In contrast to naı ¨ve
spleen populations, MZ B cells were virtually absent from spleen
cell populations derived on day 10 of an AnTat 1.1 T. brucei
infection. Indeed, Fig. 1A (lower panel) shows that all three surface
staining combinations indicate a drastic reduction in the % of MZ
B cells. In order to calculate the reduction IgM
+MZ B cell
numbers, the R2 gate was used (Fig. 1B). It is important to stress
here that during experimental trypanosome infections, a marked
splenomegaly takes place [38], resulting in a significant increase by
day 10 post-infection of the total amount of cells present within the
spleen (Fig. 1C). Hence, in order to incorporate the increase in cell
number due to splenomegaly, the % data obtained by FACS was
used to obtain the total IgM
+MZ B cell count per spleen.
Combined, these data clearly show that even when the increased
splenic cellularity of infected mice is taken into account, a
significant reduction of splenic IgM
+MZ B cell numbers takes
place right after the first week of infection. In order to visualize the
Figure 1. Alterations of Marginal Zone (MZ) B cells during T. brucei infections. MZ B cells were detected using FACS as CD21
HighCD23
Low
(R1), IgD
IntIgM
High (R2) or B220
+CD1d
+ (R3) on spleen cells derived from non- infected mice (A, upper FACS panel ) or day 10 T. brucei AnTat 1.1E-
infected mice (A, lower FACS panel). The decrease in total number of MZ B-cells per spleen was calculated for different time points during infection
(B), based on the total amount of cells harvested per spleen at each time point (C). Calculations were performed on cells harvested from 3 individual
spleens per time point. Values represent the mean6SD. One of four representative experiments is shown.
doi:10.1371/journal.ppat.1000078.g001
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independent strategy was applied. The MZ, delineated by the
marginal sinus in the spleen, contained two distinct macrophage
populations, marginal metallophilic macrophages (MMM) and
marginal zone macrophages (MZM) which localize to the inner
and outer rim of the MZ, respectively [39]. By day 10 post-
infection, T. brucei caused a nearly complete loss of MZM and
MMM, identified by the ER-TR9 and MOMA-1 markers,
respectively (Fig. 2). Further analysis of the spleen remodeling,
revealed that beside the loss of MZ, the entire spleen structure
encompassing white and red pulp is lost permanently, confirming
previous data [40].
Besides IgM
+MZ B cells, splenic B cell populations comprise
mainly Follicular (Fo) B cells and plasma (Pl) or germinal center B
cells, depending upon the immune status of the host. Given the
destruction of the spleen micro-architecture and the absence of
induction of germinal center formation during infection, both Fo B
and Pl B cell populations were further analyzed in detail by FACS.
In naı ¨ve mice Fo B cells appear as distinct splenic population
expressing CD21
IntCD23
High, IgM
IntIgD
High that distinguishes
them from CD21
HighCD23
Low, IgM
HighIgD
Int expressing MZ B
cells. They represent up to 25% of the total cell count in a naı ¨ve
spleen (see Fig 1A). Plotting the alteration in Fo B cell numbers
during a T. brucei AnTat 1.1 infection shows that also these cell
counts decrease towards the end of infection, albeit not with the
same magnitude as the MZ B-cells (Fig. 3A). In contrast, when
plasma B cells are considered a clear and very significant increase
of cell numbers during the first 10 days of infection is observed,
that coincided with the disappearance of the MZ B-cells (Fig. 3B).
However, these cells rapidly decrease in number again over time,
although they always remain significantly increased as compared
to naı ¨ve plasma spleen B cell counts. Here plasma B cells were
characterized by surface expression of B220
+CD138
+markers.
Figure 3C shows the clear increased percentage of double positive
spleen cells on day 10 post-infection, and the relative reduction
observed by day 17. When these cells were stained for IgM and
CD138, about 50% stained double positive throughout infection,
while the others stained IgM
2CD138
+ (data not shown).
T. brucei infection induced B cell apoptosis
The FACS data presented above indicate that MZ B cells are
rapidly lost during the first 10 days of a T. brucei infection. Besides
the possible differentiation of these cells into IgM
+ plasma cells, we
addressed whether apoptosis also contributes to the permanent loss
of MZ B-cells. To do so, CD21
HighCD23
Low MZ B cells were
stained for Annexin V and 7AAD at several time points of the
early infection. Figure 4A indicates the induction of apoptosis in
this cells population, following the first parasitemia wave and
coinciding with the rapid disappearance of the population. In
order to independently confirm the induction of infection-
associated apoptosis in MZ B cells, CD21
HighCD23
Low cells were
FACS-sorted and lysed for Western Blot analysis of caspase-3
activation, using a specific antibody recognizing both pro-caspase
3 (32 kDa) and the cleaved caspase 3 bands of 12 and 17 kDa that
occur when the apoptosis is taking place. As shown in Fig. 4B,
lysate from infection-derived MZ B-cells showed the induced
presence of all three caspase 3 forms, while lysates from naı ¨ve MZ
B cells, loaded on the SDS-PAGE at the same protein
concentration, did not score positive for caspase-3 activation.
Additionally, we performed a number of quantitative Real-
Time PCR, measuring mRNA levels for caspase-3 as well as
mRNA levels coding for the anti-apoptotic protein Bcl-2 and the
BAFF receptor (BAFF-R), mainly expressed on B cells and
critically involved in B cell homeostasis [28]. Due to the fact that
the time consuming FACS sorting technique risked affecting
caspase-3 mRNA levels, RT-PCR was here performed on CD19+
MACS highly enriched splenic B cells. Figure 4C shows a
significant increase in mRNA for caspase-3 (confirming the WB
result presented in Fig. 4B) and down-regulation of mRNA levels
for the anti-apoptotic Bcl-2 protein and BAFF-R 7 days post-
infection. This pro-apoptotic gene regulation preceded the
disappearance of the MZ B cells from the spleen.
T. brucei infections abrogate ex vivo B cell proliferation
The RT-PCR data presented above indicates that T. brucei
infections induce apoptosis in populations of IgM
+ spleen MZ B cells
and MACS sorted CD19+ cells, hence, the later population was used
to assess the effect of the infection on the IgM
+B cell proliferative
response. The sorted cells were incubated for 24 hours with different
concentrations of anti-IgM Fab or LPS. Figure 5A indicates that
naı ¨ve splenic B cells contain a cell fraction that is highly responsive to
IgM Fab activation and proliferation. This fraction is absent in
spleens of T. brucei infected C57Bl/6 mice 10 days after infection
(Fig. 5B). Also when cells were stimulated in a non-specific manner
withLPS, naı ¨ve CD19+Bcellsshoweda dosedependentproliferative
response (Fig. 5C), while infection derived affected B cells showed a
complete inhibition of LPS-mediated proliferation (Fig. 5D).
The loss of IgM
+ B cells and protective IgM responses
renders mice susceptible to re-challenge with T. brucei
In order to analyze the consequence of the loss of B cell
populations and in particular IgM
+ B cells on the anti-
trypanosome immune response, a series of re-challenge experi-
ments were performed. Here, mice were infected with the
pleomorphic AnTat 1.1 T. brucei parasite (that was used in all
previous experiments presented in this paper) (Fig. 6A). The first
VAT (VSG antigenic type) that emerges during this infection
corresponds to the AnTat 1.1 VSG, while later parasitemia peaks
correspond to subsequent VATs. In a separate experiment, mice
were infected with the monomorphic AnTat 1.1 and MITat 1.4
parasites, representing clones that do not switch their VAT during
their short and highly virulent infection (Fig. 6B/C). Next,
Figure 2. Destruction of spleen marginal zones. The MZ
macrophage populations of non-infected (upper panel) and day 10 T.
brucei AnTat 1.1 infected (lower panel) C57Bl/6 mice are visualized by
section staining with ER-TR9 (anti-MZM) (A,C) and MOMA-1 (anti-MMM)
antibodies (B,D) (400x magnification).
doi:10.1371/journal.ppat.1000078.g002
B-Cell Dysfunction in Trypanosomiasis
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re-challenge with parasites expressing a previously encountered
VAT.
The first re-challenge experiment was performed at day 10.
This time point corresponds to the time point of infection in which
infection-induced IgM
+ plasma cells reach peak numbers (see
Fig. 3), and is accompanied by peak levels of anti-trypanosome
serum IgM titers that were previously shown to occur at day 10
[16]. Figure 6D shows that here a complete VAT/VSG-specific
protection is obtained against the monomorphic AnTat 1.1 clone
but not against the non-related MITat 1.4 parasite clone. This
protection was retained in T-cell deficient nude mice (nu/nu)
(Fig. 6E) but was absent in B-cell deficient mMT mice (Fig. 6F),
suggesting that the protective immune response relies entirely on
T-independent B-cell responses.
Next, a re-challenge experiment was done at day 17,
corresponding to the time point where both IgM
+MZ and IgM+
plasma B-cells were dramatically reduced. Here, both the AnTat
1.1 and MiTat 1.4 clones killed the mice rapidly (Fig. 6G). These
results show that the AnTat 1.1 specific antibody mediated
protection acquired by day 10 post-primary infection was already
lost by day 17. A re-challenge experiment at day 24 confirmed the
permanent loss of VSG-specific immunity (data not shown).
T. brucei infection abrogates vaccine induced protection
against a non-related pathogen such as Bordetella
pertussis
Following the finding that VAT-specific immunity is rapidly lost
during trypanosome infections, we investigated whether T. brucei
infection may have a general detrimental effect on the immune
response generated by vaccination. As there is no efficient vaccine
available against trypanosomes we tested whether T. brucei
infection may abrogate the vaccine-induced protective immune
response against a non-related pathogen such as B. pertussis. In
order to do so, the commercially available DTPa vaccine was
used. This vaccine protects children against infections such as B.
pertussis, diphtheria and tetanus. The DTPa vaccination scheme
has been well established and standardized in mice [36,37]. It
includes one vaccination and one booster after three weeks with
the DTPa that leads to the induction of a specific protective
antibody response. As indicated in Fig. 7, in contrast to non-
vaccinated mice, DTPa vaccinated mice that were challenged with
B. pertussis clear the bacteria from the lungs. However, this DTPa
vaccine-mediated protective effect was abrogated in vaccinated
mice that suffered a T. brucei infection prior to B. pertussis challenge.
These results indicated that a T. brucei infection is capable of
abrogating the efficacy of the vaccine-induced protective responses
against non-related pathogens such as B. pertussis.
Discussion
To date a large body of evidence is available addressing the
molecular mechanisms underlying antigenic variation in African
Trypanosomes. Antigenic variation is considered to be advanta-
geous for the parasite as it permits continuous change of the
surface antigenic coat and allows the parasites to evade antibody-
mediated elimination [3,7]. Here we demonstrate that in addition,
trypanosome infections also cause the significant loss of various B
cell populations and extensively remodel splenic micro-architec-
Figure 3. Alteration of Follicular and Plasma B cell numbers during T. brucei infections. The number of follicular B cells (A) as well as
plasma B cells (B) per spleen was calculated on different days after T. brucei AnTat 1.1E infection. Calculations were performed on cells harvested from
3 individual spleens per time point. Values represent the mean6SD. One of four representative experiments is shown. Plasma spleen B cells were
stained with a B220/CD138 combination (C).
doi:10.1371/journal.ppat.1000078.g003
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protective anti-parasite antibody responses, (ii) prevent the
development of effective B-cell memory against encountered
variant antigenic parasite types (VATs), and (iii) abrogate vaccine-
induced protective responses to non-related pathogen such as B.
pertussis in a setting where a commercially available human vaccine
for diphtheria, tetanus and B. pertussis (DTPa) was used in an
experimental mouse model.
Trypanosome infections are known to induce B cell unrespon-
siveness to mitogens and to induce polyclonal B-cell activation. In
addition, highly virulent infections in which mice fail to control the
first peak of infection have been shown to result in the rapid
elimination of splenic FoB cells [31]. However, as natural
trypanosome infections develop into a chronic phase, we analyzed
here the fate of various splenic B cell populations throughout the
course of an experimental T. brucei infection, using a more chronic,
multi-wave pleomorphic model. In the spleen, B-cell populations
can be subdivided into marginal zone (MZ) B cells, follicular (Fo) B
cells, plasma (Pl) and germinal center B cells, as well as transitional
T1 and T2 B cells [23,24,25,26]. Our results first of all confirm
previous data and show that in the early stage pleomorphic T.
brucei infection extensive spleen remodeling gives rise to a rapid
induction of spenomegaly due to cell proliferation and the influx of
cells into the spleen [19,38]. The detailed analysis of the splenic
cell populations showed that following the first parasitemia peak
mature B220
+CD138
+ plasma B cell numbers significantly
increased, and that both IgM
+ and IgM
2 plasma cells accumu-
lated at this stage. Later on in infection, B220
+GL7
+/PNA+
‘germinal center’ B cells accumulated in the spleen as well, despite
the absence of actual germinal center formation during trypano-
some infections [40]. Interestingly, while ongoing trypanosome
infections continuously generate new parasite antigentic types,
major p1asma B cell induction occurs only at the beginning of
infection in a response to the first encountered parasite VAT.
Coinciding to this early plasma B cell induction, we recorded the
total destructions of the spleen marginal zone (MZ), accompanied
by the disappearance of the MZ B cell population, characterized
as B220
+IgM
HighIgD
IntCD21
HighCD23
Low CD1d
+CD138
2 cells
[26]. As the spleen marginal zone (MZ) separates the T- and B-cell
containing white pulp from the blood filled sinuses of the red pulp,
the MZ is involved in the capture of blood-born pathogens, the
regulation of lymphocyte trafficking, and the induction of antigen
specific T-independent B cell responses, mostly resulting in IgM
secretion [23,24]. Important here is that previously published data
Figure 4. Infection-induced apoptosis of MZB cells. CD21
HighCD23
Low cells were gated and analyzed for 7AAD and Annexin V
staining. The percentage of positive cells was calculated in MZ B cells from naı ¨ve mice, as well as from T. brucei AnTat 1.1E infected mice on days 4, 7
and 10 (A). CD21
HighCD23
Low cells were FACS sorted on day 7, lyzed and analyzed in Western Blot with an anti-caspase 3 antibody, showing bands at
32 kD (pro-caspase 3), and cleaved forms 17 kD and 12 kD (B). RT-PCR for Casp3, BAFF-R, and Bcl-2 was performed on CD19
+ spleen cells isolated from
naı ¨ve mice as well as from T. brucei-infected mice on day 4 and day 7 (C). Results present the means of 3 mice per time point 6SD. One of three
representative experiments is shown.
doi:10.1371/journal.ppat.1000078.g004
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crucial in trypanosome clearance during ongoing infection
[16,17,22]. Using a VSG-specific re-challenge model, we now
show that the infection-associated destruction of the IgM
+ MZ B
cell compartment results in the rapid loss of IgM-mediated VSG
specific protection against re-infection with a previously encoun-
tered parasite.
The infection-associated disappearance of the MZ B cells from
the spleen could be explained by two independently occurring
mechanisms, being cell differentiation and/or cell death. Sup-
porting the first is the observation that the rapid disappearance of
MZ B cells coincided with the temporary accumulation of IgM
+
plasma cells. However, a direct link between these two events
remains speculative, as no specific markers exist that allow cell fate
analysis that would proof the MZ B cell origin of the occurring
plasma cells. Hence, in order to address this possibility, we aimed
at reconstituting JH
2/2 B-cell deficient mice with naı ¨ve IgM
+ B
cells. During T. brucei infections however, this approach did not
result in efficient B cell repopulation or the accumulation of IgM
+
plasma cells (unpublished results S. Black). On the other hand, our
results suggest that the rapid disappearance of MZ B cells does
involve the induction of parasitemia-associated B-cell apoptosis.
Indeed analysis of the CD21
HighCD23
Low MZ B cells that remain
in the spleen in the days following the clearance of the first peak of
parasitemia, revealed that these cells upregulated Annexin V
expression and in large stained positive for 7AAD. In addition, the
induction of caspase 3 gene expression as well as the conversion of
pro-caspase 3 into the cleaved 12 kD and 17 kD caspase 3
activation products in this cell population, suggests the induction
of trypanosomiasis-associated apoptosis in the splenic MZ B cell
population. Moreover, the affected MZ B cells showed down-
regulation of mRNA for the anti-apoptotic Bcl-2 protein, involved
in the inhibition of caspase 3 activation through the cytochrome C
pathway [28]. Finally, also the mRNA expression for the B cell
specific BAFF-R was reduced in the vanishing MZ B cell
population. This receptor normally governs B cell homeostasis
and provides an NF-kB activation signal that regulates the mRNA
levels for the anti-apoptotic Bcl2 protein [27,28]. Interesting to
note here is that parasite-induced B-cell apoptosis has previously
also been reported to occur in experimental infections with the
intracellular T. cruzi parasite. In this case however, the process was
mediated by Fas/Fas Ligand interactions resulting in B cell-B cell
fratricide, selectively affecting IgG
+ B-cells [41].
In an independent approach, T. brucei induced spleen
dysfunction was assessed by immunohistochemistry. Here we
show the profound destruction of splenic MZ micro-architecture is
marked by the loss of MZM and MMM (macrophage)
populations. Detailed analysis of the spleen remodeling, revealed
that beside the loss of MZ architecture, the entire spleen structure
encompassing white and red pulp is lost, showing the absence of
germinal center formation. This destruction of splenic micro-
architecture occurred during the first peak of infection, and was
permanent. Due to the destruction of the spleen microarchitecture
in combination with (i) the alteration of splenic B cell surface
Figure 5. T. brucei induced abrogation of B cell proliferation. CD19
+ MACS sorted cells derived form control mice or T.brucei AnTat 1.1E
infected mice (day 10 post infection) were incubated for 24 h in the presence of different doses of anti-IgM Fab (A,B), or different doses of LPS (C,D).
Proliferation was measure by thymidine incorporation. Results were obtained using spleen cell preparations of four individual mice, and represent the
mean % of CPM increase 6SD, with the 100% showing the mean CPM level of non-stimulated cells.
doi:10.1371/journal.ppat.1000078.g005
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peritoneal infection with of 5000 living parasites, using pleomorphic AnTat 1.1 (A), cloned monomorphic AnTat 1.1 (B), and unrelated cloned
monomorphic MITat 1.4 (C) parasites (MS: Median survival). Re-challenge experiments were performed as presented in the insert box. Survival was
recorded for the primary pleomorphic AnTat 1.1 infection (&), and mice re-challenged with the cloned monomrophic AnTat 1.1 (%) or MiTat 1.4 (*)
parasites on day 10, in WT mice (D), T-cell deficient nu/nu mice (E), and B-cell deficient mMT mice (F). A re-challenge was subsequently also performed
on day 17 in WT mice (G). In each experiment 10 mice per experimental condition were used. One out of three representative experiments is shown
for every experimental condition.
doi:10.1371/journal.ppat.1000078.g006
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immunohistochemistry could unfortunately not be used for the co-
localization of apoptotic markers and specific MZ B cell markers.
Important to note here is that remodeling of spleen cell
architecture has also been reported in other experimental parasite
infection models. Indeed, experimental Plasmodium chabaudi
infections in mice also cause major disruptions in the splenic cell
distribution as well as the splenic micro-architecture. However, as
this infection is self-curing, in contrast to experimental trypano-
some infections, these changes were found to be temporary [42].
The last B cell aspect presented in this paper, deals with the
question of whether T. brucei infection can actively abrogate a
vaccine-induced protective memory immune response. This point
is extremely relevant to address in the context of multiple ongoing
vaccination programs in the human African population such as the
recent WHO Meningitis Vaccine Project (MVP), and the Pediatric
Dengue Vaccine Initiative (PDVI), and in the context of future
anti- HIV/AIDS and anti-malaria vaccine programs. To address
this question, we applied the commercially available human DTPa
vaccine against diphtheria, tetanus and B. pertussis in a T. brucei
mouse model [36,37]. While our findings showed the expected
protective vaccine response in control vaccinated and B. pertussis
challenged mice, the DTPa efficacy was abolished after the
vaccinated host was infected with T. brucei parasites. These results
indicate that the ongoing trypanosome infection either depleted
the memory B cell compartment that was first generated during
the DTPa vaccination, or prevented the reactivation of the
memory response. Taking into account that the commercially
available DTPa vaccine [37] is routinely used in Africa and other
countries to protect children against diphtheria, tetanus, and B.
pertussis, our results raise the worrying possibility that the protective
potential of this vaccine can be abolished by a later encounter with
T. brucei parasites, exposing the individual to secondary infection
hazards and abolishing previous health efforts. In this context it is
remarkable to note that studies performed 3 decades ago already
indicated that T. brucei infections abrogate B cell memory
responses to thymus-dependent and thymus-independent antigens
using DNP-KLH and DNP-Ficoll as antigens for vaccination [29].
Additionally, earlier investigations in domestic animals showed
that infections with African trypanosomes abrogate the efficacy of
several commercial vaccines against the foot and mouth disease,
swine fever, anthrax spores, Brucella abortis and louping-ill vaccine
[43,44,45,46,47]. However, till now no attention has been given to
the consequences of T. brucei infections on the immune response
induced by commercially available human vaccines. In addition,
these findings have not been seriously considered in recent years
when (failed) anti-trypanosome vaccination efforts were reported.
Indeed several attempts have now been made to develop anti-
trypanosome vaccines using relatively non-variant trypanosome
antigens, but none of these attempts have been successful so far,
despite the initial induction of antigen-specific antibody responses
[8,48,49,50]. In view of the results presented here, it is possible
that the rapid trypanosome driven B-cell dysfunction upon host
contact with living parasites contributed to these vaccine failures.
Our studies suggest that only vaccines that strongly suppress the
level of initial parasitemia peak or induce immediate sterile
immunity would be likely to have sufficient efficacy in trypano-
somiasis susceptible hosts. In addition, it is crucial to realize that
due to the constraints of conventional strategies, most vaccination
protocols lead to the induction of T-dependent high affinity IgG
responses. Taking into account that the protective response against
previously encountered VAT present in ‘day 10’ re-challenged
mice was T-independent and IgM-mediated, this poses an
additional obstacle for vaccine development, as till now no
strategies exist to generate long lasting high affinity IgM responses.
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Figure 7. Trypanosomiasis associated elimination of non-
related host antibody responses. Mice were vaccinated with the
commercial DPTa vaccine and boosted after three weeks. 14 days after
the vaccine boost, mice were infected with 5000 T. brucei AnTat 1.1E
parasite by intra-peritoneal injection, followed 10 days later by an
intranasal challenged with 5610
6 CFU of B. pertussis/mouse (&).
Control groups consisted of non-vaccinated B. pertussis challenged mice
(6), and DPTa vaccinated mice that were challenged with B. pertussis 24
days after the second DTPa boost (%). Mice were sacrificed 3h and 3, 5
and 8, days after challenge and lung homogenates were prepared and
plated on the Bordet-Gongou agar plates. CFU’s were measured after
72 h incubation. Values are represented as the mean6SD of 3
individual mice per time point.
doi:10.1371/journal.ppat.1000078.g007
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